Welcome to Beacon Equity Research. Today is Friday, 21 December 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Contact Us     Charity     Affiliates    

Aastrom (ASTM) Shares Remain Active with the Recent Placement Agency Agreement with BMO

A personís life span depends on the lifestyle and the kind of environment he lives in.  Modern technology has developed means to make life easier and get things done with less effort in a shorter period of time.  With the advent of modern medicine, ways to improve health and prolong life span have also been developed.  This is the aim of regenerative medicine, i.e., to help the natural healing process work faster and / or use special materials to regrow missing or damaged organs or tissues.  Average life expectancy before the modern time era was from 20 to 35.  But with the advent of modern medicine, this has increased.  Some people even predict that half of the babies born in North America and Japan since 2000 will live up to 90, and 10% to 100. 

Aastrom Biosciences, Inc. (Aastrom) focuses on regenerative medicine with emphasis on autologous cells.  Autologous cells are those taken from an individual, cultured (or stored), and, possibly, genetically manipulated before being transferred back into the original donor. Transurethral injections of autologous cells could relieve stress urinary incontinence in women.  Stress urinary incontinence has become common among women nowadays, thus demand for the product will consequently increase. 

Aastrom recently entered into a Placement Agency Agreement with BMO Capital Markets, Corp.  This agreement is for a registered direct offering of 11,842,105 shares of Aastrom's common stock and warrants to purchase up to 5,921,053 shares of Aastrom's common stock for certain institutional investors.  Under the agreement, shares of common shares and warrants will be sold in the form of units which consist of one share of common stock and warrants to purchase 0.5 shares of common stock.  This is priced at $1.14 per unit. The gross revenue from this offering is estimated by Aastrom to reach up to $13.5 million.

About Aastrom Biosciences, Inc. (OBTCC: ASTM)

Aastrom Biosciences, Inc. was founded in 1989 and has its headquarters in Ann Arbor Michigan.  It is a regenerative medicine company which focuses on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues based on its proprietary Tissue Repair Cell (TRC) technology.  This technology is based on its cell products, which are a unique cell mixture containing large numbers of stem and progenitor cells, produced outside of the body from a small amount of bone marrow taken from the patient, and the means to produce these products in an automated process.  For more information, you may visit the companyís website at: http://www.aastrom.com

< Prev   Next >

Copyright 2007 Beacon Equity Research